Skip to main content
Top
Published in: Familial Cancer 3/2017

01-07-2017 | Short Communication

Identification of MSH2 inversion of exons 1–7 in clinical evaluation of families with suspected Lynch syndrome

Authors: Maureen E. Mork, Andrea Rodriguez, Melissa W. Taggart, Miguel A. Rodriguez-Bigas, Patrick M. Lynch, Sarah A. Bannon, Y. Nancy You, Eduardo Vilar

Published in: Familial Cancer | Issue 3/2017

Login to get access

Abstract

Traditional germline sequencing and deletion/duplication analysis does not detect Lynch syndrome-causing mutations in all individuals whose colorectal or endometrial tumors demonstrate mismatch repair (MMR) deficiency. Unique inversions and other rearrangements of the MMR genes have been reported in families with Lynch syndrome. In 2014, a recurrent inversion of MSH2 exons 1–7 was identified in five families suspected to have Lynch syndrome. We aimed to describe our clinical experience in identifying families with this specific inversion. Four probands whose Lynch syndrome-associated tumors demonstrated absence of MSH2/MSH6 staining and who had negative MMR germline testing were evaluated for the MSH2 inversion of exons 1–7, offered during initial genetic workup or upon routine clinical follow-up. All four probands tested positive for the MSH2 inversion. Proband cancer diagnoses included colon and endometrial adenocarcinoma and sebaceous adenoma. A variety of Lynch syndrome-associated cancers were reported in the family histories, although only one family met Amsterdam II criteria. Thirteen at-risk relatives underwent predictive testing. MSH2 inversion of exons 1–7 was found in four probands previously suspected to have Lynch syndrome based on family history and tumor testing. This testing should be offered routinely to patients with tumors demonstrating loss of MSH2/MSH6 staining.
Literature
2.
go back to reference Moller P, Seppala T, Bernstein I et al (2015) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. doi:10.1136/gutjnl-2015-309675 PubMed Moller P, Seppala T, Bernstein I et al (2015) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. doi:10.​1136/​gutjnl-2015-309675 PubMed
6.
7.
8.
go back to reference Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41(1):112–117. doi:10.1038/ng.283 CrossRefPubMed Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41(1):112–117. doi:10.​1038/​ng.​283 CrossRefPubMed
9.
go back to reference Chen JM (2008) The 10-Mb paracentric inversion of chromosome arm 2p in activating MSH2 and causing hereditary nonpolyposis colorectal cancer: re-annotation and mutational mechanisms. Genes Chromosomes Cancer 47(6):543–545. doi:10.1002/gcc.20556 CrossRefPubMed Chen JM (2008) The 10-Mb paracentric inversion of chromosome arm 2p in activating MSH2 and causing hereditary nonpolyposis colorectal cancer: re-annotation and mutational mechanisms. Genes Chromosomes Cancer 47(6):543–545. doi:10.​1002/​gcc.​20556 CrossRefPubMed
Metadata
Title
Identification of MSH2 inversion of exons 1–7 in clinical evaluation of families with suspected Lynch syndrome
Authors
Maureen E. Mork
Andrea Rodriguez
Melissa W. Taggart
Miguel A. Rodriguez-Bigas
Patrick M. Lynch
Sarah A. Bannon
Y. Nancy You
Eduardo Vilar
Publication date
01-07-2017
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9960-y

Other articles of this Issue 3/2017

Familial Cancer 3/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine